Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

Nations begin signing protocol on biodiversity access and benefit-sharing (IP Watch) (IP tango)

Would Canada-EU trade proposals add $2.8 billion price tag to drugs bill? (IP Watch) (Michael Geist)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

Nations begin signing protocol on biodiversity access and benefit-sharing (IP Watch) (IP tango)

New biodiversity benefit-sharing protocol relies on national rules, experts say (IP Watch)

Are patents a double-edged sword? Perspective matters (Profitability through Simplicity)

Would Canada-EU trade proposals add $2.8 billion price tag to drugs bill? (IP Watch) (Michael Geist)

UK: ‘Patent box’ tax incentives and SPCs in the UK (The SPC Blog)

US: BIO commends Senate Judiciary Committee passage of Patent Reform Act of 2011 (PatentlyBIOtech)

US: Sen. Kohl introduces bill to prohibit reverse payments (Patent Docs)

US: Office of Generic Drugs finished 2010 on a high note – really high! (FDA Law Blog)

US: Another academic with solutions to problems that don’t exist (Patent Docs)

US: Syngenta files for declaratory judgment of invalidity and non-infringement of Bayer’s patents based on its development of GM crops containing HPPD gene (Patent Docs)

US: District Court New Jersey: Loss of market share to infringing competitor during six year reexamination warrants denial of stay: Wyeth et al v Abbott (Docket Report)

US: District Court New Jersey: Court precludes jury argument “extolling benefits of generic drug pricing” but permits evidence of generic and name brand pricing: Sanofi-Aventis v Glenmark (Docket Report)

US: AMP v USPTO – Breifing update III (Patent Docs)

US: Physician’s lament: Let’s give away new drug for free (America-Israel Patent Law)

Products

Actonel (Risedronate) – US: Warner Chilcott files patent infringement complaint against Teva following Para IV certification filing (Patent Docs)

Advair (Fluticason, Salmeterol) – Netherlands: District Court of The Hague invalidates Glaxo’s patent for lack of inventive step (in line with UK, IE, DE): Sandoz, Hexal v Glaxo  (EPLAW) (Generic Pharmaceuticals and IP)

Advair Diskus (Fluticasone, Salmeterol) – Canada Federal Court: Off-colour trademark decision leaves Glaxo purple with frustration: Apotex Inc v Registrar of Trademarks (Canadian Trademark Blog)

Angiomax (Bivalirudin) – US: The fat lady goes back to her dressing room; Federal Circuit denies MDCO motions in ANGIOMAX PTE litigation: Medicines Company v Kappos (FDA Law Blog)

Antara (Fenofibrate) – US: Lupin files patent infringement complaint against Paddock following Para IV certification filing (Patent Docs)

Benlysta (Belimumab) – US: Human Genome Sciences seeks declaratory judgment of non-infringement, and patent invalidity and uneforceability based on their Benlysta product (Patent Docs)

Boniva (Ibandronate) – US: Hoffmann-La Roche files patent infringement complaint against Mylan, GenPharm following Para IV certification filing (Patent Docs)

Botox (OnabotulinumtoxinA) – China: The missing well known mark regulation -BOTOX vs BOOSTOX (IP Komodo Dragon)

Comtan (Entacapone) – US: Orion files patent infringement complaint against Mylan following Para IV certification filing (Patent Docs)

PhosLo GelCaps (Calcium) – US: Fresenius Medical Care files patent infringement complaint against Zydus following Para IV certification (Patent Docs)

Proscar (Finasteride) – France: Tribunal de Grande Instance dosage regime not patentable: Actavis v Merck (Kluwer Patent Blog)

Silenor (Doxepin) – US: Somaxon files patent infringement complaint against Par following ANDA filing (Patent Docs)

Synagis (Palivizumab), Tysabri (Natalizumab), Soliris (Eculizumab) – US: Novartis Vaccines and Diagnostics files patent infringement suit against MedImmune (Patent Docs)

Taxotere (Docetaxel) – Australia: A turning point for interlocutory injunctions in patent cases- FCA dismisses Sanofi-Aventis’ application for interlocutory injunction allowing Hospira and Interpharma to launch generics pending outcome of trial (Mallesons Stephen Jaques)

 Welchol (Colesevelam) – US: Daiichi Sankyo files patent infringement complaint against Watson Pharmaceuticals following Para IV certification filing (Patent Docs)